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A B S T R A C T
Background: The association between obesity surgery (OS) and cancer risk remains unclear. We investigated this
association across the English National Health Service. A population-based Swedish study has previously sug-
gested that OS may increase the risk of developing colorectal cancer (CRC).
Methods: A retrospective observational study of individuals who underwent OS (surgery cohort) or diagnosed
with obesity, but had no OS (no-surgery cohort) (1997–2013) were identiﬁed using Hospital Episode Statistics.
Subsequent diagnosis of CRC, breast, endometrial, kidney and lung cancer, as well as time ‘at risk’, were de-
termined by linkage to National Cancer Registration & Analysis Service and Oﬃce of National Statistics data,
respectively. Standardised incidence ratios (SIR) in relation to OS were calculated.
Results: 1 002 607 obese patients were identiﬁed, of whom 3.9% (n=39 747) underwent OS. In the no-surgery
obese population, 3 237 developed CRC (SIR 1.12 [95% CI 1.08–1.16]). In those who underwent OS, 43 de-
veloped CRC (SIR 1.26 [95% CI 0.92–1.71]). The OS cohort demonstrated decreased breast cancer risk (SIR 0.76
[95% CI 0.62–0.92]), unlike the no surgery cohort (SIR 1.08 [95% CI 1.04–1.11]). Increased risk of endometrial
and kidney cancer was observed in surgery and no-surgery cohorts.
Conclusions: CRC risk is increased in individuals diagnosed as obese. Prior obesity surgery was not associated
with an increased CRC risk. However, the OS population was small, with limited follow-up. Risk of breast cancer
after OS is reduced compared with the obese no-surgery population, while the risk of endometrial and kidney
cancers remained elevated after OS.
1. Introduction
Obesity is linked to an increased risk of several malignancies, in-
cluding colorectal (CRC) [1–3] post-menopausal breast [4–6], en-
dometrial [7,8] and kidney cancers [9,10]. Obesity (also known as
bariatric) surgery (OS) is an eﬀective treatment for weight reduction
providing metabolic and cardiovascular beneﬁts[11]. In parallel with
the increased prevalence of obesity, there has been a signiﬁcant in-
crease in the frequency of OS [12]. Traditional OS procedures such as
gastric banding and Roux-en-Y gastric bypass (RYGB), which induce
weight loss via restrictive and combined restrictive/malabsorbtive
mechanisms respectively, are the most commonly performed world-
wide [11]. Over the last decade, sleeve gastrectomy has emerged as an
alternative procedure [11,13].
The eﬀect of OS on future risk of CRC is not clear.
Counterintuitively, there is evidence that OS may increase the long-
term risk of developing CRC despite post-operative weight loss [14–17].
The eﬀect appears to be time-dependent, with the risk of CRC in-
creasing with time from surgery, which would be consistent with the
long natural history of colorectal carcinogenesis. It is plausible that
colorectal carcinogenesis may be driven by changes in diet and the gut
microbiota post-bariatric surgery [18,19]. By contrast, a meta-analysis
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of four observational studies, which have reported CRC incidence after
OS, concluded that overall OS is associated with a 27% lower risk of
subsequent CRC [20].
However, all studies to date, except one population-based Swedish
study [14] have been limited in their follow-up time after OS (less than
ten years) and sample size (so statistical power) to fully explore the
association with incident CRC [21–23]. We aimed therefore, to conﬁrm
or refute the ﬁndings of the Swedish study in a separate independent
population. We tested the hypothesis that there is an increase in CRC
incidence following OS in a large population-based cohort of in-
dividuals who had undergone OS in England, also determining the risk
of other obesity-related cancers for comparison.
2. Methods
2.1. Design
This was a national population-based retrospective observational
data-linkage study of individuals over the age of 18 and below 95 years,
who had an episode of in-patient or day-case care in an English NHS
hospital involving a primary diagnosis of obesity or OS. Study approval
was obtained from the Health Research Authority Conﬁdentiality
Advisory Group (CAG) (CAG reference: CAG 4-09(b)/2013) and
Research Ethics Committee (REC reference: 13/YH/0204). This re-
search was funded by World Cancer Research Fund International
(WCRF) and Cancer Research UK (CRUK).
Patients diagnosed with obesity were identiﬁed using the
International Classiﬁcation of Diseases Version 10 (ICD10): E66 code.
OS was deﬁned as an episode of care with a primary diagnosis of
obesity with an Oﬃce of Population Censuses and Surveys (OPCS)
Classiﬁcation of Interventions and procedures (4th revision) procedure
code for a surgical procedure listed in Table 1. These individuals were
identiﬁed using a Hospital Episode Statistics (HES) dataset containing
hospital admissions between April 1997 and September 2013. We re-
viewed OPCS4 codes used by NHS Digital (previously the Health and
Social Care Information Centre) in previous analyses and excluded
several procedures that were either; 1) very unlikely to be performed as
OS, or 2) were a revision, reversal or maintenance procedure [24,25].
Table 1 details the codes used by NHS Digital and the codes used in this
study. If individuals within this cohort had multiple episodes of care of
the same type recorded (OS or obesity without surgery), then the ﬁrst
episode of care took precedence. If an individual had both OS and
obesity no surgery episodes recorded then the surgery episode was
used.
The cohort was linked to the National Cancer Registration &
Analysis Service (NCRAS) dataset to determine if these individuals re-
ceived, subsequent to the index episode (OS or obesity alone), a diag-
nosis of CRC (ICD10 C18-C20), breast (ICD10 C50), kidney (ICD10 C64)
or endometrial (ICD10 C54) cancer, which are all cancers known to be
linked to obesity [14,16,26]. In contrast, lung cancer (ICD10: C33-C34)
is not obesity-related [26] but was included as a control as its incidence
should be unaﬀected by OS. Lastly, upper gastrointestinal cancers
(esophageal cancer (ICD-10: C15), stomach cancer (ICD-10: C16), small
intestine cancer (ICD-10: C17), liver cancer (ICD-10: C22), gallbladder
cancer (ICD-10: C23), extrahepatic bile duct cancer (ICD10: C24) and
pancreatic cancer (ICD10: C25)) were included in the data as the codes
used to identify OS are similar to those used for surgical procedures
used to manage these cancers. Individuals with upper gastrointestinal
cancers were subsequently excluded from the analyses.
The cohort was linked to the Oﬃce for National Statistics (ONS)
mortality dataset to determine individual time at risk of cancer diag-
nosis. This was deﬁned as the time from the index episode to cancer
diagnosis, death or the censor date (30th September 2013).
The characteristics of the groups who did and did not undergo OS,
subsequently referred to as surgery and no-surgery cohorts, were
compared. This revealed a relatively high proportion of individuals that
apparently underwent OS a short period after a diagnosis of cancer.
These operations were likely to be associated with cancer management
rather than to treat obesity. Thus, all individuals who developed a
cancer within one year of the index episode were excluded.
2.2. Statistical analysis
The standardized incidence ratio (SIR) with 95% conﬁdence in-
terval (CI) was calculated as an estimate of relative risk of both surgery
and no-surgery obese participants diagnosed with a cancer instead of
making a direct comparison between the two cohorts that could be
confounded by diﬀerences in age, calendar year and other risk factors.
The SIR was calculated as the ratio of the observed number of cancer
cases in the study population to the number that would be expected if
that population experienced the same cancer incidence rates as the
background English population, dependent on age and calendar period.
This was achieved by splitting follow-up time into one-year age cate-
gories and one-year calendar periods and each age-period-sex group
was then linked with cancer incidence rates in England obtained from
NCRAS. The expected number of cancer cases was calculated for both
the surgery and no-surgery cohorts by multiplying the observed person
time by age, sex and calendar year-speciﬁc cancer incidence rates for
England. The follow-up time after OS was classiﬁed as: 1 to 2 or ≥2
years. All person-time during the ﬁrst year after surgery or diagnosis of
obesity was excluded because of the risk of erroneous identiﬁcation of
procedures associated with cancer resection or palliation, rather than
OS, or earlier detection of CRC due to hospitalization or obesity sur-
gery. This widened exclusion by reducing all individuals’ risk time by
one year, and not only those who were diagnosed with cancer within
one year from the index event. Finally, the observed and expected
numbers of deaths were summed and divided. The SIR with 95% CI was
estimated under the assumption that the observed number of events
followed a Poisson distribution.
3. Results
3.1. Patients
A total of 1 056 392 patients were initially identiﬁed. After exclu-
sions, the ﬁnal dataset consisted of 1 002 607 individuals, including; 39
747 (3.9%) recorded as having OS and the remainder (962 860; 96.0%)
as having an episode of hospital care due to obesity without OS (Fig. 1).
Table 2 details the characteristics of the two groups. The majority of
patients in both groups were female; 76.6% in the OS group and 62.9%
in the obese no OS group. The OS group was younger than the no
surgery group, with a mean age of 44.8 and 53.1 years, respectively.
The majority of OS (91.7%) took place after 2006 and this restricted the
potential follow-up time after surgery to six years for the majority of
this population. The OS group had a median follow-up period of 3.0
years (range 1–16 years) and 144 677 person-years of follow-up. The
equivalent ﬁgures for the obese no OS group were a median follow-up
time of 2.5 years (range 1–16 years) and 3 608 882 person-years at risk.
3.2. Risk of colorectal cancer
There were 43 new diagnoses of CRC in the OS group and 3 237 new
diagnoses in the obese no OS group. Table 3 shows the SIR for CRC
diagnosis in the two groups, after exclusion of all person-time within
one year from the OS surgery or hospital attendance associated with
obesity. Comparisons were not made directly between the two groups,
but between each group and the English background population. The
absolute cumulative incidence of CRC in the surgery group was lower
(30 per 100 000 person-years) than that in the no surgery group (91 per
100 000 person-years), which is likely explained by the younger age of
the surgery cohort. The overall SIR for CRC in the surgery cohort was
not signiﬁcantly increased compared to the background English
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population (SIR: 1.26 95% CI: 0.92–1.71). There was, however, a
slightly increased CRC risk in individuals who did not undergo surgery
(SIR: 1.12, 95% CI: 1.08–1.16) compared to the background population.
In the surgery group, an increased risk of CRC was observed in the
oldest (≥50 years) age group (SIR: 1.47, 95% CI: 1.02–2.06). In the no-
surgery group, the SIR of CRC was higher in males (SIR: 1.21, 95% CI:
1.15–1.26) than in females (SIR: 1.02, 95% CI: 0.97–1.08). The risk of
CRC was higher in the no-surgery group in the latest calendar period
(2006–2013) (SIR: 1.16, 95% CI: 1.12–1.21) compared to the earliest
period (1995–2005) (SIR: 0.94, 95% CI: 0.86–1.02).
3.3. Risk of other obesity-related and non-obesity-related cancers
Table 4 shows the SIR of breast, endometrial or kidney cancer
(obesity-related cancers) and lung cancer (not obesity-related) diag-
nosis. There was an overall decreased risk of breast cancer after OS
(SIR: 0.76, 95% CI: 0.62–0.92), and slightly increased risk in obese
individuals who did not undergo OS (SIR: 1.08, 95% CI: 1.04–1.11).
The risk of endometrial cancer was increased by nearly 3-fold for both
groups (SIR: 2.98, 95% CI: 2.25–3.90, for surgery and SIR: 2.60, 95%
CI: 2.48–2.73, for no-surgery groups) compared with the background
population. The risk of kidney cancer was increased approximately 3-
fold after OS (SIR: 3.06, 95% CI: 2.08–4.34) and almost 2-fold in obese
individuals who did not undergo OS (SIR: 1.78, 95% CI: 1.68–1.89).
The risk of lung cancer was, however, reduced in the surgery group
(SIR: 0.70, 95% CI: 0.46–1.03) while it was slightly raised in the no-
surgery group (SIR: 1.09, 95% CI: 1.05–1.13).
4. Discussion
This study demonstrates that elevated CRC risk continues after OS,
in individuals who underwent OS over the age of 50 years, an age-range
at which a signiﬁcant number of OS procedures are undertaken [27]. By
contrast, surgery and accompanying weight loss were associated with
reduced breast cancer risk, unlike the no-surgery comparator group, in
which breast cancer risk was consistently elevated compared with the
background population. There is limited literature available examining
the association between obesity surgery and cancer risk. Two Swedish
studies [14,16], showed an association between bariatric surgery and
increased risk of obesity-related cancers during long-term follow-up,
whilst other studies with limited power to interpret CRC-speciﬁc risk
have shown the opposite phenomenon [20,21,23,28].
Methodological strengths of this study include the population-based
cohort design, which reduced selection bias and the large size of the
cohort. Another signiﬁcant strength of this study is the high com-
pleteness and validity of the linked HES and NCRAS datasets used in
Table 1
Oﬃce of Population Censuses and Surveys 4th revision (OPCS4) codes deﬁned as obesity surgery (OS) by NHS Digital and this study.
3-Digit OPCS4 Code 4-Digit OPCS4 Code Description NHS Digital This Study
G01 G011 – G019 excision of oesophagus and stomach *
G02 G021 – G029 total excision of oesophagus *
G03 G031 – G039 partial excision of oesophagus *
G27 G271 – G279 total excision of stomach *
G28 G281 partial gastrectomy and anastomosis of stomach to duodenum *
G282 partial gastrectomy and anastomosis of stomach to transposed jejunum * *
G283 partial gastrectomy and anastomosis of stomach to jejunum NEC * *
G284 sleeve gastrectomy and duodenal switch * *
G285 sleeve gastrectomy NEC * *
G288 other speciﬁed partial excision of stomach * *
G289 unspeciﬁed partial excision of stomach * *
G30 G301 gastroplasty not elsewhere classiﬁed * *
G302 partitioning of stomach * *
G303 partitioning of stomach using band * *
G304 partitioning of stomach using staples *
G305 maintenance of gastric band *
G308 other speciﬁed plastic operation on stomach * *
G309 plastic operation on stomach NOS * *
G31 G310 – G319 connection of stomach to duodenum *
G32 G320 conversion from previous anastomosis of stomach to transposed jejunum *
G321 bypass of stomach by anastomosis of stomach to transposed jejunum * *
G322 revision of anastomosis of stomach to transposed jejunum * *
G323 conversion to anastomosis of stomach to transposed jejunum * *
G324 closure of connection of stomach to transposed jejunum *
G325 attention to connection of stomach to transposed jejunum * *
G328 other speciﬁed connection of stomach to transposed jejunum * *
G329 unspeciﬁed connection of stomach to transposed jejunum * *
G33 G330 conversion from previous anastomosis of stomach to jejunum NEC *
G331 revision of anastomosis of stomach to jejunum NEC * *
G332 conversion to anastomosis of stomach to jejunum nec * *
G333 closure of connection of stomach to jejunum NEC * *
G334 open reduction of intussusception of gastroenterostomy *
G335 closure of connection of stomach to jejunum *
G336 attention to connection of stomach to jejunum * *
G338 other speciﬁed other connection of stomach to jejunum * *
G339 unspeciﬁed other connection of stomach to jejunum * *
G38 G387 removal of gastric band *
G388 other speciﬁed * *
G48 G481 – G486 other operations on stomach *
G49 G491 – G499 excision of duodenum *
G51 G511 bypass of duodenum by anastomosis of stomach to jejunum * *
G513 bypass of duodenum by anastomosis of duodenum to jejunum *
G61 G611 bypass of jejunum by anastomosis of jejunum to jejunum *
G619 bypass of jejunum by anastomosis of jejunum to colon *
G71 G716 duodenal switch *
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previous studies [29–33]. Studies using these data have shown that the
ﬁnal linked dataset is stronger and richer than its component parts
(cancer registration and hospital admissions) with robust recording of
cancer incidence [34,35]. In addition the process of linkage enables the
identiﬁcation of duplicates in both datasets, so their combination im-
proves the overall quality of the data available.
There are, however, several important limitations of the data, upon
which the study was based, which should be highlighted. The obese no
surgery cohort represents a small subset of the obese UK population,
since it includes those individuals who have been admitted or had an
outpatient or A&E appointment related to obesity. The study was ori-
ginally intended to replicate a previous population-based Swedish study
[14], which showed an association between OS and increased risk of
Fig. 1. Record identiﬁcation and exclusions from the
Hospital Episode Statistics (HES) datasets for the
obesity surgery (OS) and obese no OS groups.
Table 2
Characteristics of the obesity surgery (OS) group and the obese no OS group identiﬁed in
HES between 1997 and 2013 excluding all cancers diagnosed within 1 year from index
episode.
OS, number (%) Obese no OS, number (%)
Total 39,747 100.0% 962,860 100.0%
Gender
Male 9311 23.4% 356,855 37.1%
Female 30,436 76.6% 606,005 62.9%
Age groups at entry into the
cohorts, years
18–39 12,552 31.6% 247,032 25.7%
40–49 13,957 35.1% 154,197 16.0%
≥50 13,238 33.3% 561,631 58.3%
Calendar year
1997–2005 3282 8.3% 168,684 17.5%
2006–2013 36,465 91.7% 794,176 82.5%
Follow-up time, years
≤2 13,021 32.8% 402,879 41.8%
>2 26,726 67.2% 559,981 58.2%
Surgery type
Restrictive surgery 20,649 52.0% – –
Restrictive and
malabsorbtive surgery
19,098 48.0% – –
Table 3
Risk of colorectal cancer expressed as the standardized incidence ratio (SIR) with 95%
conﬁdence interval (lower conﬁdence limit (LCL), upper conﬁdence limit (UCL)) in the
obesity surgery (OS) and the obese no OS groups.
Variable OS Obese No OS
n SIR LCL UCL n SIR LCL UCL
Total 43 1.26 0.92 1.71 3237 1.12 1.08 1.16
Gender
Male 16 1.41 0.81 2.29 1850 1.21 1.15 1.26
Female 27 1.19 0.79 1.74 1387 1.02 0.97 1.08
Age groups at entry into the
cohorts, years
18–39 2 0.79 0.10 2.85 54 1.35 1.02 1.77
40–49 7 0.83 0.34 1.72 174 1.19 1.02 1.38
≥50 34 1.47 1.02 2.06 3009 1.11 1.07 1.15
Calendar year
1997–2005 5 2.17 0.70 5.07 497 0.94 0.86 1.02
2006–2013 38 1.20 0.85 1.65 2740 1.16 1.12 1.21
Follow-up time, years
1–2 26 1.24 0.81 1.81 1706 1.14 1.09 1.20
≥2 17 1.32 0.77 2.11 1531 1.10 1.04 1.15
Surgery type
Restrictive surgery 29 1.41 0.94 2.02 – – – –
Restrictive and
malabsorptive surgery
14 1.05 0.57 1.76 – – – –
Table 4
Standardized incidence ratios (SIRs) with 95% conﬁdence intervals (lower conﬁdence
limit (LCL), upper conﬁdence limit (UCL)) for non-colorectal cancers in the obesity sur-
gery (OS) and the obese no OS groups.
Cancer site OS Obese No OS
n SIR LCL UCL n SIR LCL UCL
Breast 101 0.76 0.62 0.92 3806 1.08 1.04 1.11
Uterus 54 2.98 2.25 3.90 1758 2.60 2.48 2.73
Kidney 31 3.06 2.08 4.34 1110 1.78 1.68 1.89
Lung 26 0.70 0.46 1.03 3645 1.09 1.05 1.13
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CRC, using a larger English population and, hence, with greater sta-
tistical power. Whilst the initial extract of data, however, comprised 1
002 606 individuals (13-times bigger than the Derogar et al. study), the
number of individuals in the OS group was signiﬁcantly lower (4% of
the total obesity population), as the OS rates in England have increased
only recently in response to increased obesity incidence. Additionally,
the limited follow-up time in this study was likely not suﬃcient for a
statistically signiﬁcant association of OS with CRC risk to be revealed
(median follow-up three years). On the contrary, in the Swedish study
OS patients were followed-up for a considerably longer period of time
(mean follow-up time nine years) allowing a statistically signiﬁcant
association to be revealed.
Another limitation of this study is the fact that no deﬁnitive list of
OPCS4 codes for OS exists and other studies have used diﬀerent codes
[24,25,36]. The codes used in this study were based on those used in
previous NHS Digital reports [24,25] excluding some codes in order to
make our analysis more speciﬁc. For instance, oesophagogastrectomy
and anastomosis of oesophagus to stomach (OPCS 4: G011) was ex-
cluded as it was anticipated that such an extensive procedure including
the extraction of oesophagus and stomach was probably not intended to
be for obesity management. Another example of a code that we ex-
cluded is conversion from previous anastomosis of stomach to duo-
denum (OPCS 4: G310). We excluded 4865 cases, anticipated not to be
related to OS, which led to a smaller (but more speciﬁc) cohort than
originally anticipated. In addition, the codes in HES for OS overlap with
procedures for some cancer procedures. At the outset this was not an-
ticipated to inﬂuence our cohort signiﬁcantly as only episodes of care
with a primary diagnosis of obesity (and not cancer) were included.
However, the data extract that we received from NHS Digital did con-
tain a large number of OS procedures that were undertaken around the
time of the diagnosis of a cancer and these were assumed to be surgery
linked to cancer treatment. Exclusion of these cases necessarily reduced
the size of the cohort available for subsequent analysis.
Sensitivity analyses were conducted using the full list of OS proce-
dures used by NHS Digital in previous publications [24,25]. This did
not signiﬁcantly aﬀect the results. Although there were marked dif-
ferences between the list used by NHS Digital and the one used in our
analysis, the number of procedures identiﬁed with suﬃcient follow-up
to inﬂuence the results were small. In consequence, little diﬀerence was
observed. Once further follow-up data are available then such analyses
would be more revealing.
Furthermore, some of the codes used to indicate OS (notably sleeve
gastrectomy (G285) and gastric banding (G303)) were not introduced
into the OPCS4 coding system until April 2006. It was not clear, prior to
this date, what codes were being used in HES for these procedures. This
resulted in fewer ‘bariatric’ procedures being identiﬁed in the 9 years of
the study period prior to their introduction, and signiﬁcantly more
subsequently. This had the eﬀect of both further reducing the size of the
cohort but also, importantly, limiting the follow-up time for the OS
group. The unexpectedly small sample having undergone OS was an-
other diﬀerence from the previous Swedish study [14]. In that study,
20% of the population underwent OS compared to only 4% in the
current study. Indeed, Sweden has the second highest rate of use and
the highest levels of spending per capita on OS in Europe [37], while
England has the ﬁfth highest rate. In addition, the clinical indications
for use of the surgery vary between the two countries with Sweden
oﬀering the procedure to all at a body mass index (BMI) of 40 kg/m2
with no serious co-morbidities [37], whilst English patients are also
required to have an undergone an intensive weight loss programme for
at least 12–24 months (6 months for those with BMI>50 kg/m2) prior
to surgery. Evidence suggests that OS is used in Sweden for individuals
with lower BMIs and less comorbidity than in England [37].
Our population-based linkage study did not include data on BMI and
other risk factors for CRC [38]. Data on BMI after OS, obtained through
linkage to primary care data are required to investigate further the
association between OS and CRC risk in the UK. Such data would also
provide the opportunity to perform a preliminary investigation of
whether colorectal adenoma risk increases after OS, as benign color-
ectal adenoma is a recognized biomarker of CRC risk [39] allowing a
shorter follow-up period in a cohort study. Other risk factors such as
ethnicity, socioeconomic status or insurance status were not available
in this dataset.
It should be recognized that patients undergoing OS are likely to
have diﬀerent characteristics to those who did not have surgery, in-
cluding age and presence of obesity-related co-morbidities. These
characteristics are also associated with the incidence of obesity-related
cancers. In addition, obese people who do not have OS may be at a
higher risk of non-cancer related morbidity and mortality [40–42].
Again, this may inﬂuence our ﬁndings by leading to a higher censoring
rate, and so shorter follow-up time, in the non-surgery versus the OS
cohort. This bias could not be taken into account due to insuﬃcient
information in the routine data on relevant factors.
An unexpected ﬁnding was the high SIRs for kidney and en-
dometrial cancer in both OS and obese no OS groups compared with the
background population. We do not believe that this is explained by
erroneous coding of cancer-related surgery as all cancer diagnoses oc-
curring within one year after the diagnosis of obesity were excluded
and the SIR was signiﬁcantly above unity even in the obese no OS
group. Both cancers are recognized as having a strong association with
excess body weight [7–9]. The SIR that we observed for endometrial
cancer is similar to the relative risk associated with increasing body
mass index in the UK Million Women study [43]. However, a recent
systematic review and meta-analysis has suggested that endometrial
cancer risk is reduced after OS [44]. Subsequent lung cancer risk was
lower in those who underwent OS compared with the obese no OS
group which likely reﬂects non-smoker selection bias for OS. Pre-
viously, it has been reported that excess body weight is protective for
lung cancer, especially in current and former smokers [26,45].
4.1. Conclusions
In conclusion, using a population-based data linkage approach, we
report increased CRC risk in individuals diagnosed as obese. Although
the interpretation of whether OS is associated with subsequent higher
CRC risk was limited by the small OS group size and restricted follow-
up time after OS, the data indicated statistically signiﬁcant increased
SIRs in obese patients older than 50 years at the time of the surgery.
This could be due to longer exposure to obesity before OS, something
that requires further investigation. We also report that OS is associated
with reduced breast cancer risk, unlike the obese comparator group.
Finally, we report high SIRs for renal and endometrial cancers in the
presence or absence of prior OS, which warrants further investigation.
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